Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharming Group N.V (PHAR) Profit After Tax: 2020-2025

Historic Profit After Tax for Pharming Group N.V (PHAR) over the last 4 years, with Sep 2025 value amounting to $90.2 million.

  • Pharming Group N.V's Profit After Tax rose 8824.95% to $90.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.7 million, marking a year-over-year increase of 397.78%. This contributed to the annual value of -$11.8 million for FY2024, which is 12.26% down from last year.
  • According to the latest figures from Q3 2025, Pharming Group N.V's Profit After Tax is $90.2 million, which was up 972.66% from -$10.3 million recorded in Q2 2025.
  • In the past 5 years, Pharming Group N.V's Profit After Tax ranged from a high of $90.2 million in Q3 2025 and a low of -$14.6 million during Q4 2022.
  • For the 3-year period, Pharming Group N.V's Profit After Tax averaged around $3.6 million, with its median value being -$5.7 million (2024).
  • Its Profit After Tax has fluctuated over the past 5 years, first surged by 40,507.77% in 2022, then slumped by 1,879.82% in 2023.
  • Over the past 5 years, Pharming Group N.V's Profit After Tax (Quarterly) stood at $16.0 million in 2021, then plummeted by 191.54% to -$14.6 million in 2022, then surged by 98.02% to -$289,000 in 2023, then surged by 1,089.27% to $2.9 million in 2024, then surged by 8,824.95% to $90.2 million in 2025.
  • Its Profit After Tax was $90.2 million in Q3 2025, compared to -$10.3 million in Q2 2025 and $2.9 million in Q4 2024.